The E2F2 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the E2F2 gene in the human HAP1 cell background. This product provides a versatile loss-of-function model for investigating E2F2-dependent transcriptional programs and their roles in cell cycle progression, oncogenesis, and signal transduction. The polyclonal format preserves population-level heterogeneity while enabling robust functional studies without the clonal selection bottlenecks associated with single-cell-derived knockouts. Researchers can expect a heterogeneous pool of edited alleles, reflecting a broad range of gene disruption events across the cell population.
The HAP1 host cell line is a near-haploid human cell model originally derived from the KBM-7 chronic myeloid leukemia line. Its suspension-adapted growth and near-haploid karyotype make it exceptionally well-suited for high-throughput functional genomics screens, drug sensitivity profiling, and genetic perturbation studies. The reduced genetic complexity minimizes redundant gene copies, enhancing the penetrance of CRISPR-mediated knockouts and facilitating clear genotype-phenotype correlations. HAP1 cells retain key features of myeloid leukemia, including intact p53 and PI3K-Akt signaling pathways, offering a physiologically relevant context for cancer biology research.
E2F2 is a critical transcription factor that, upon heterodimerization with DP family proteins (TFDP1 and TFDP2), binds to E2F-responsive promoters and drives the expression of genes essential for the G1/S transition and DNA replication. Among its downstream targets are cyclin E1 (CCNE1), cyclin A2 (CCNA2), CDC6, CDT1, and the MCM2-7 helicase complex. E2F2 activity is tightly regulated by the retinoblastoma protein (RB1) and related pocket proteins RBL1/p107 and RBL2/p130. Mitogenic signalling cascades, including CDK4/CDK6?Ccyclin D complexes, phosphorylate RB family members, relieving repression of E2F2 and enabling cell cycle entry. E2F2 also contributes to apoptosis regulation through transcriptional activation of ARF (CDKN2A) and the BH3-only protein BBC3 (PUMA), linking it to the p53 tumor suppressor network.
In the HAP1 leukemia background, E2F2 knockout provides a powerful tool for dissecting oncogenic cell cycle control mechanisms. Dysregulation of E2F family members is a hallmark of numerous malignancies, including leukemia, breast cancer, hepatocellular carcinoma, and glioma. The near-haploid nature of HAP1 ensures that single-copy disruption of E2F2 can produce unambiguous loss-of-function phenotypes, accelerating the identification of E2F2-specific dependencies and synthetic lethal interactions. This model is particularly valuable for studying how leukemic cells rewire transcriptional programs to sustain proliferation and for validating targets within the RB-E2F axis.
Typical applications include functional genomics of cell cycle control, cancer dependency mapping, drug target validation for E2F-driven malignancies, and investigation of apoptotic signalling. Researchers can monitor E2F2 protein levels by Western blotting, quantify target gene expression via RT-qPCR, assess cell cycle distribution by flow cytometry, and measure proliferation or apoptosis using Annexin V assays. Transcriptome-wide effects can be profiled by RNA-seq, and direct E2F2 chromatin interactions can be mapped by ChIP-qPCR. For further technical information or custom inquiries, please contact Ascent Research.
